Clinical Trial Update: A Phase II Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Moderate to Severe Glabellar Lines [Phase 2]

View source ↗

Summary

A Phase II clinical trial evaluating the efficacy and safety of MBA-P01 in adults with moderate to severe glabellar lines has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glabellar Frown Lines
• Glabellar Lines

Drugs mentioned

• MBA-P01

Snippet

Sponsor: Medytox Korea | Conditions: Glabellar Frown Lines | Phase 2 | Status: COMPLETED